Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HRAS drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HRAS Mutant Proteins (G12V, G12C, Q61R) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View HRAS Products |
| Gene Delivery | HRAS Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HRAS Products |
| Benchmark Ab | Anti-HRAS Benchmark Antibody Recombinant positive control for assay validation. |
View HRAS Products |
| Validator | HRAS siRNA Set For knockdown verification and specificity checks. |
View HRAS Products |
| Related Target A | KRAS Essential for isoform selectivity and counter-screening assays. |
View KRAS Products |
| Related Target B | SOS1 Critical upstream GEF; targeted for synergistic pathway inhibition. |
View SOS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (vs KRAS/NRAS) | Comprehensive RAS homolog panels (HRAS, KRAS, NRAS) strictly verified by mass spectrometry. |
| Targeting Specific Mutants | Extensive mutant library (G12C, G12V, G13D, Q61R) available with >95% purity. |
| Nucleotide State Control | High-purity soluble proteins suitable for controlled GDP/GTP loading in SPR and enzymatic assays. |
| False Positives in Cell Assays | Sequence Verified siRNA and Lentivirus for rigorous target validation and knockdown. |
Live HRAS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HRAS therapeutics is intensifying, with major players shifting focus from traditional broadly-acting agents to highly selective small molecule inhibitors. While farnesyltransferase inhibitors (FTIs) have paved the clinical path for HRAS-mutant head and neck squamous cell carcinomas (HNSCC), the next wave of R&D is targeting direct mutant-specific inhibition. Leveraging the breakthrough designs of KRAS G12C inhibitors, developers are now designing covalent and non-covalent molecules specifically tailored to the HRAS binding pockets to overcome acquired resistance and reduce off-target toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (FTI) | Kura Oncology | HNSCC, Urothelial Carcinoma | Cellular Phenotypic Assays (Need high-titer Lentivirus for stable cell lines) |
| Small Molecule (Direct Inhibitor) | Preclinical Biotech Innovators | Solid Tumors (HRAS Mutated) | Selectivity Assay (Need High-Purity Mutant vs WT Proteins, KRAS/NRAS panels) |
| Combination Therapies | Novartis, Mirati (BMS) | Refractory Solid Tumors | Pathway Validation (Need SOS1/SHP2/MEK proteins for combinatorial screening) |